MedTrace Logo

Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)

NCT05322889 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-08-28

No results posted yet for this study

Summary

Phase IIa clinical trial will be conducted with patients requiring in-label paclitaxel-chemotherapy due to ovarian or breast cancer. The efficacy of a 12-week telmisartan treatment, starting one week before planned paclitaxel-administration to prevent PIPNP (paclitaxel-induced peripheral neuropathic pain) will be assessed by measurement of occurrence of clinical symptoms of PIPNP as well as lipid profiles

Conditions

  • Neuropathic Pain
  • Chemotherapy Effect

Interventions

DRUG

Telmisartan tablets

12 weeks treatment

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    collaborator OTHER

  • Dr. Frank Behrens

    lead OTHER

Principal Investigators

  • Martin Sebastian, MD · Department of Haematology/Medical Onkology, University Hospital, Goethe-University Frankfurt

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2022-10-04
Completion
2023-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322889 on ClinicalTrials.gov